Disruptions to the network can cause disease, e.g., activating mutations in the signaling protein BRAF is present in 40–50% of all melanoma tumors, i.e., skin cancer, and single target treatments are not always sufficient due to cellular adaptations, e.g., tumors often acquire resistance to BRAF-inhibitors5. This evidence concerns the gene BRAF and skin cancer.